Treatment of metastatic colorectal cancer: focus on panitumumab

Rebecca Y Tay; Rachel Ee San Wong; Eliza Hawkes

doi:10.2147/CMAR.S71821

Treatment of metastatic colorectal cancer: focus on panitumumab

Rebecca Y Tay, Rachel Ee San Wong, Eliza Hawkes

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

16 Citations (Scopus)

Abstract

Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

Original language	English
Pages (from-to)	189 - 198
Number of pages	10
Journal	Cancer Management and Research
Volume	7
DOIs	https://doi.org/10.2147/CMAR.S71821
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/CMAR.S71821

Cite this

@article{f875237d3b434a078104fb7db79fbef0,

title = "Treatment of metastatic colorectal cancer: focus on panitumumab",

abstract = "Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.",

author = "Tay, {Rebecca Y} and Wong, {Rachel Ee San} and Eliza Hawkes",

year = "2015",

doi = "10.2147/CMAR.S71821",

language = "English",

volume = "7",

pages = "189 -- 198",

journal = "Cancer Management and Research",

issn = "1179-1322",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Treatment of metastatic colorectal cancer: focus on panitumumab

AU - Tay, Rebecca Y

AU - Wong, Rachel Ee San

AU - Hawkes, Eliza

PY - 2015

Y1 - 2015

N2 - Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

AB - Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

UR - https://www.dovepress.com/treatment-of-metastatic-colorectal-cancer-focus-on-panitumumab-peer-reviewed-fulltext-article-CMAR

U2 - 10.2147/CMAR.S71821

DO - 10.2147/CMAR.S71821

M3 - Article

VL - 7

SP - 189

EP - 198

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -

Treatment of metastatic colorectal cancer: focus on panitumumab

Abstract

UN SDGs

Access to Document

Other files and links

Cite this